Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Pioneering antisense drug heads into pivotal trials for Huntington disease.

Mullard A.

Nat Rev Drug Discov. 2019 Mar;18(3):161-163. doi: 10.1038/d41573-019-00018-7. No abstract available.

PMID:
30824887
2.

Inhibition of Huntington synthesis by antisense oligodeoxynucleotides.

Nellemann C, Abell K, Nørremølle A, Løkkegaard T, Naver B, Röpke C, Rygaard J, Sørensen SA, Hasholt L.

Mol Cell Neurosci. 2000 Oct;16(4):313-23.

PMID:
11085870
3.

Improved metrics for Huntington's disease trials.

Arney K.

Nature. 2018 May;557(7707):S46-S47. doi: 10.1038/d41586-018-05179-w. No abstract available.

PMID:
29844554
4.

Oligonucleotide therapeutic approaches for Huntington disease.

Sah DW, Aronin N.

J Clin Invest. 2011 Feb;121(2):500-7. doi: 10.1172/JCI45130. Epub 2011 Feb 1. Review.

5.

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.

van Roon-Mom WMC, Roos RAC, de Bot ST.

Nucleic Acid Ther. 2018 Apr;28(2):59-62. doi: 10.1089/nat.2018.0720. Epub 2018 Mar 13.

PMID:
29620999
7.

Antisense oligonucleotide technologies in drug discovery.

Aboul-Fadl T.

Expert Opin Drug Discov. 2006 Sep;1(4):285-8. doi: 10.1517/17460441.1.4.285.

PMID:
23495899
8.

Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy.

Barr AN, Heinze WJ, Dobben GD, Valvassori GE, Sugar O.

Neurology. 1978 Nov;28(11):1196-1200.

PMID:
152416
9.

Therapy development in Huntington disease: From current strategies to emerging opportunities.

Dickey AS, La Spada AR.

Am J Med Genet A. 2018 Apr;176(4):842-861. doi: 10.1002/ajmg.a.38494. Epub 2017 Dec 8. Review.

PMID:
29218782
10.

Translating Antisense Technology into a Treatment for Huntington's Disease.

Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, Kordasiewicz H.

Methods Mol Biol. 2018;1780:497-523. doi: 10.1007/978-1-4939-7825-0_23. Review.

PMID:
29856033
11.
12.

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR.

PLoS One. 2014 Sep 10;9(9):e107434. doi: 10.1371/journal.pone.0107434. eCollection 2014.

13.

Efficiency of antisense oligonucleotide drug discovery.

Bennett CF.

Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):215-24. Review.

PMID:
12162703
14.

Antisense and RNAi: powerful tools in drug target discovery and validation.

Lavery KS, King TH.

Curr Opin Drug Discov Devel. 2003 Jul;6(4):561-9. Review.

PMID:
12951819
15.

Antisense oligonucleotide-based therapeutics for cancer.

Dean NM, Bennett CF.

Oncogene. 2003 Dec 8;22(56):9087-96. Review.

PMID:
14663487
16.

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.

Wallach JD, Ciani O, Pease AM, Gonsalves GS, Krumholz HM, Taylor RS, Ross JS.

BMC Med. 2018 Mar 21;16(1):45. doi: 10.1186/s12916-018-1023-9.

17.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

18.

Recent advances in the therapeutic development for Huntington disease.

Mestre TA.

Parkinsonism Relat Disord. 2018 Dec 12. pii: S1353-8020(18)30529-7. doi: 10.1016/j.parkreldis.2018.12.003. [Epub ahead of print]

PMID:
30616867
19.

Use of antisense oligonucleotides in functional genomics and target validation.

Ravichandran LV, Dean NM, Marcusson EG.

Oligonucleotides. 2004 Spring;14(1):49-64. Review.

PMID:
15104896
20.

Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.

Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai JS, Dayalu P.

J Neurol. 2018 Jun;265(6):1443-1453. doi: 10.1007/s00415-018-8852-5. Epub 2018 Apr 23.

PMID:
29687215

Supplemental Content

Support Center